KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $7.0 billion.

  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity rose 11.15% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 billion, marking a year-over-year increase of 5.70%. This contributed to the annual value of $7.0 billion for FY2024, which is 2.15% up from last year.
  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity amounted to $7.0 billion in FY2024, which was up 2.15% from $6.8 billion recorded in FY2023.
  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity's 5-year high stood at $7.0 billion during FY2024, with a 5-year trough of $5.8 billion in FY2020.
  • Over the past 3 years, Biomarin Pharmaceutical's median Liabilities and Shareholders Equity value was $6.8 billion (recorded in 2023), while the average stood at $6.7 billion.
  • Data for Biomarin Pharmaceutical's Liabilities and Shareholders Equity shows a peak YoY increased of 24.69% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Liabilities and Shareholders Equity stood at $5.8 billion in 2020, then grew by 2.68% to $6.0 billion in 2021, then grew by 6.17% to $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then rose by 2.15% to $7.0 billion in 2024.